Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05879679
Other study ID # 2024-4019, 22336
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 8, 2024
Est. completion date October 2025

Study information

Verified date June 2024
Source Laval University
Contact Gabrielle Hudon, Msc
Phone +14186568711
Email equipe.iceta@criucpq.ulaval.ca
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Craving is defined as an irrepressible urge to consume certain products and represents one of the key factors in severe substance use disorders, as illustrated by its recent inclusion as a diagnostic criterion in the most recent fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM 5). However, the pathophysiological models of craving remain debated. The "metacognitive hub model", a conceptual, experimental and clinical approach to craving, proposes that craving should be considered as the embedded consequence of the interaction between three components (the reflexive, automatic and interoceptive systems), each of which has an implicit and explicit element. This model links the three components by suggesting that metacognitive abilities, the ability to understand one's own cognitive functioning, may be a skill of individuals that allows them to make the three sub-components explicit or not. To date, the conception of eating disorders is increasingly similar to that of addictive disorders. Indeed, there is growing evidence that the symptomatology of bulimia nervosa and binge eating disorder can be considered in part as an "food addiction" and would fit the diagnostic criteria of an addictive disorder. Bulimia nervosa is an eating disorder (DSM 5) characterized by a cycle of binge eating and compensatory behaviors such as self-induced vomiting that tend to negate or compensate for the effects of the binge eating. Binge eating disorder (DSM 5) is characterized by a cycle of binge eating, but without the compensatory behaviors seen in bulimia nervosa. In addition, there are common neurological aspects as well as similar cognitions between these eating disorders and addictive disorders. Given the importance of craving in addictive pathology, it seems essential to address this issue in bulimia nervosa and binge eating disorder. The cognitive difficulties of patients with bulimia nervosa and binge eating disorder, which are close to the difficulties observed in patients with addictive behaviors, suggest that the "metacognitive hub model" could provide a clear and measurable theoretical framework of the different dimensions of craving. The overall objective of this project is to explore the relationship between the level of craving induced by food picture exposure and the level of impairment of the reflexive, automatic, interoceptive, and metacognitive systems in women with bulimia nervosa and binge eating disorder and to compare these impairments according to the nature of the eating disorder (i.e., binge eating versus bulimia nervosa). Our hypotheses are: 1. the induction of food craving will affect the reflexive, automatic, and interoceptive systems of patients with bulimia nervosa and binge eating disorder. 2. the magnitude of the effect of food craving induction on implicit craving and explicit craving will be modulated by the participants' metacognitive abilities.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date October 2025
Est. primary completion date September 2025
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - have been medically diagnosed with binge eating disorder or bulimia nervosa - fluent in french - able to consent Exclusion Criteria: - co-morbid substance use disorder, - pregnancy or breastfeeding

Study Design


Intervention

Behavioral:
Food craving induction
Standardized craving induction procedure will be used, based on exposure to food-related images (https://www.lippc2s.fr/food-cal-pictures/). Craving intensity will be measured by visual analogic scale before and after the induction sequence.

Locations

Country Name City State
Canada Centre d'expertise Poids, Image et Alimentation (CEPIA) Québec
Canada IUCPQ Québec
France Université de Nantes Nantes

Sponsors (4)

Lead Sponsor Collaborator
Laval University Centre d'expertise Poids, Image et Alimentation (CEPIA), Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec, Université de Nantes

Countries where clinical trial is conducted

Canada,  France, 

Outcome

Type Measure Description Time frame Safety issue
Other Age Baseline
Other Gender Baseline
Other Biological sex Baseline
Other Weight Baseline
Other Height Baseline
Other Body Mass Index (BMI) Weight / Height2 Baseline
Other Waist and hips circumferences in cm Baseline
Other Menopausal status or contraception Baseline
Other Socio-professional category Number of participants per socioprofessional category as defined by statistic canada Baseline
Other Medical history and concomitant treatment Rates of various associated diseases (e.g., cardiovascular, digestive disorders). Type of medications (antidepressants, antipsychotics, hypotensive drugs) and their rates. Baseline
Other Ethnic origin Baseline
Primary Attention Network Test (ANT) The ANT is a task designed to test three attentional networks in children and adults: alerting, orienting, and executive control 1 hour (after food craving induction)
Primary Dot Probe Task To test and measure selective attention 1 hour (after food craving induction)
Primary Water load task This task was originally developed to induce gastric distension and assess gastrointestinal symptoms in patients with functional digestive disorders. This task stimulates the stomach using a natural distension stimulus (i.e., water ingestion) and without the complex hormonal response of a caloric meal. 1 hour (after food craving induction)
Primary Live metacognition "live" metacognitive assessment will be done by asking the participants to rate their level of confidence on a visual analog scale ranging from 0% (I just guessed) to 100% (completely confident) for each items. 1 hour (after food craving induction)
Primary Avoidance/Approach task adapted for food craving In this task, participants are asked to move a joystick that simulates the movement of the food represented in the image. The joystick movements are accompanied by a zoom effect that increases the illusion of movement. 1 hour (after food craving induction)
Secondary Beck Depression Inventory II (BDI-II) Minimum score : 0; Maximun score : 63; Higher scores mean a worse outcome. Baseline
Secondary State-Trait Anxiety Inventory (STAI) The questionnaire includes two scales (20 items) consisting of a total of 40 questions. For each scale the minimum score is 0 and the maximun score is 80. Higher scores mean a worse outcome. Baseline
Secondary Eating Disorder Examination Questionnaire (EDE-Q) The measure provides four attitudinal subscale scores: Restraint (5 items), Eating Concern (5 items), Shape Concern (8 items), and Weight Concern (5 items). An overall Global score is the mean of the four subscale scores. Responses are on a 7-point ordinal response; minimum score : 0, maximun score: 6; higher scores mean a worse outcome. Baseline
Secondary Food Craving Questionnaire State (FCQ-S) Minimum : 15; Maximun : 75; Higher scores mean a worse outcome. Baseline
Secondary Food Craving Questionnaire Trait (FCQ-T) Minimum : 39; Maximun : 234; Higher scores mean a worse outcome. Baseline
Secondary Visual Analogic Scale of craving It represents a continuous visual progression of craving from one extreme to another, from "no craving at all" to "extreme and uncontrollable craving," with patients stating the intensity of their current craving between these two extremes. Baseline, at 1 hour (after craving induction), at 3 hours (end of the session_
Secondary Schedule for the Assessment of Insight in Eating Disorders (SAI-ED) Interview-based scale for the multidimensional assessment of insight in eating disorders. It includes three categories: illness awareness, symptom awareness, and treatment engagement. Minimum score : 0, maximun score: 29; Higher scores mean a better outcome. Baseline
Secondary Difficulties in Emotional Regulation Scale (DERS- 18) Minimum score : 18, maximun score : 90; Higher scores mean a worse outcome. Baseline
Secondary Attentional Control Scale (ACS) Minimum score : 20, maximun score : 80; Higher scores mean a better outcome. Baseline
Secondary Body Awareness Questionnaire (BAQ) Minimum score: 18; Maximun score: 126; Higher scores mean a better outcome. Baseline
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT04174703 - Preparing for Eating Disorders Treatment Through Compassionate Letter-Writing N/A
Terminated NCT04278755 - Binge Eating & Birth Control Phase 2
Withdrawn NCT02978742 - Evaluating and Implementing a Smartphone Application Treatment Program for Bulimia Nervosa and Binge Eating Disorder N/A
Withdrawn NCT00988481 - Topiramate Augmentation in Bulimia Nervosa Partial Responders Phase 4
Completed NCT00522769 - Cognitive Behavioral Therapy to Treat Bulimia Nervosa in Adolescents Phase 1/Phase 2
Completed NCT00184301 - A Comparison Study of Treatments Given to Patients With Concurrent Eating Disorder and Personality Disorder. N/A
Completed NCT00304187 - Effectiveness of Antibiotic Treatment for Reducing Binge Eating and Improving Digestive Function in Bulimia Nervosa Phase 2
Recruiting NCT04409457 - Self-Control in Bulimia Nervosa N/A
Recruiting NCT05509257 - Naltrexone Neuroimaging in Teens With Eating Disorders Early Phase 1
Recruiting NCT05937243 - Identifying Effective Technological-based Augmentations to Enhance Outcomes From Self-help Cognitive Behavior Therapy for Binge Eating N/A
Recruiting NCT05862389 - Study on the Mechanism of Eating Disorder
Recruiting NCT05728021 - Smartphone-based Aftercare for Inpatients With Bulimia Nervosa N/A
Completed NCT03781921 - The Neural Bases of Emotion Regulation in Bulimia Nervosa
Completed NCT02553824 - FDA Approved Medication to Reduce Binge Eating and/or Purging Phase 1
Terminated NCT04041024 - Decision-making and Risk-taking in Bulimia N/A
Completed NCT04265131 - Emotion Regulation in Eating Disorders: How Can Art Therapy Contribute to Treatment Outcome? N/A
Recruiting NCT06431854 - Evaluation of a New Treatment Program for Adolescents With Eating Disorders: MINERVA Program N/A
Recruiting NCT02960152 - Periodontal Impact of Eating Disorders (the PERIOED Study) N/A
Completed NCT00916071 - Association Between Attention Deficit Hyperactivity Disorder and Bulimia Nervosa in Outpatients With Eating Disorders N/A
Terminated NCT00308776 - Cholecystokinin for Reducing Binge Eating in People With Bulimia Nervosa N/A